Business Description
Exelixis Inc
NAICS : 541714
SIC : 8731
ISIN : US30161Q1040
Share Class Description:
FRA:EX9: Ordinary SharesDescription
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.12 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | 0.31 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 10.1 | |||||
| Beneish M-Score | -2.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 22.4 | |||||
| 3-Year EBITDA Growth Rate | 17.7 | |||||
| 3-Year EPS without NRI Growth Rate | 22.9 | |||||
| 3-Year FCF Growth Rate | -1.9 | |||||
| 3-Year Book Growth Rate | 7.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 44.92 | |||||
| Future 3-5Y Total Revenue Growth Rate | 9.19 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.65 | |||||
| 9-Day RSI | 53.53 | |||||
| 14-Day RSI | 52.45 | |||||
| 6-1 Month Momentum % | 67.76 | |||||
| 12-1 Month Momentum % | 57.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.93 | |||||
| Quick Ratio | 3.88 | |||||
| Cash Ratio | 3.02 | |||||
| Days Inventory | 98.3 | |||||
| Days Sales Outstanding | 48.83 | |||||
| Days Payable | 163.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1 | |||||
| Shareholder Yield % | 7.02 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.25 | |||||
| Operating Margin % | 29.22 | |||||
| Net Margin % | 22.43 | |||||
| FCF Margin % | 19.3 | |||||
| ROE % | 20.97 | |||||
| ROA % | 16.15 | |||||
| ROIC % | 27.02 | |||||
| ROC (Joel Greenblatt) % | 127.41 | |||||
| ROCE % | 24.19 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 21.28 | |||||
| Forward PE Ratio | 20.19 | |||||
| PE Ratio without NRI | 18.34 | |||||
| Shiller PE Ratio | 50.5 | |||||
| Price-to-Owner-Earnings | 30.74 | |||||
| PS Ratio | 4.78 | |||||
| PB Ratio | 4.17 | |||||
| Price-to-Tangible-Book | 4.29 | |||||
| Price-to-Free-Cash-Flow | 24.08 | |||||
| Price-to-Operating-Cash-Flow | 20.79 | |||||
| EV-to-EBIT | 13.95 | |||||
| EV-to-Forward-EBIT | 16.12 | |||||
| EV-to-EBITDA | 13.34 | |||||
| EV-to-Forward-EBITDA | 14.86 | |||||
| EV-to-Revenue | 4.08 | |||||
| EV-to-Forward-Revenue | 4.15 | |||||
| EV-to-FCF | 20.96 | |||||
| Price-to-Projected-FCF | 1.43 | |||||
| Price-to-Median-PS-Value | 0.64 | |||||
| Price-to-Graham-Number | 1.87 | |||||
| Price-to-Net-Current-Asset-Value | 10.95 | |||||
| Price-to-Net-Cash | 18.86 | |||||
| Earnings Yield (Greenblatt) % | 7.17 | |||||
| FCF Yield % | 4.27 | |||||
| Forward Rate of Return (Yacktman) % | 4.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Exelixis Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,909.114 | ||
| EPS (TTM) (€) | 1.433 | ||
| Beta | 0.16 | ||
| Volatility % | 39.07 | ||
| 14-Day RSI | 52.45 | ||
| 14-Day ATR (€) | 0.449111 | ||
| 20-Day SMA (€) | 32.5735 | ||
| 12-1 Month Momentum % | 57.79 | ||
| 52-Week Range (€) | 18.255 - 34.42 | ||
| Shares Outstanding (Mil) | 285.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Exelixis Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Exelixis Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Exelixis Inc Frequently Asked Questions
What is Exelixis Inc(FRA:EX9)'s stock price today?
The current price of FRA:EX9 is €32.63. The 52 week high of FRA:EX9 is €34.42 and 52 week low is €18.26.
When is next earnings date of Exelixis Inc(FRA:EX9)?
The next earnings date of Exelixis Inc(FRA:EX9) is 2025-02-06 Est..
Does Exelixis Inc(FRA:EX9) pay dividends? If so, how much?
Exelixis Inc(FRA:EX9) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers